NASDAQ:SNSS - Sunesis Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sunesis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.84 +0.07 (+9.08 %) (As of 02/20/2020 04:00 PM ET) Add Compare Today's Range$0.77Now: $0.84▼$0.8650-Day Range$0.34MA: $0.57▼$0.8452-Week Range$0.20Now: $0.84▼$1.77Volume1.57 million shsAverage Volume1.43 million shsMarket Capitalization$93.62 millionP/E RatioN/ADividend YieldN/ABeta2.55 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, a topoisomerase 2 inhibitor, which completed a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SNSS Previous Symbol CUSIP86732860 CIK1061027 Webhttp://www.sunesis.com/ Phone650-266-3500Debt Debt-to-Equity Ratio0.02 Current Ratio4.56 Quick Ratio4.56Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$240,000.00 Price / Sales390.08 Cash FlowN/A Price / Cash FlowN/A Book Value($0.45) per share Price / Book-1.87Profitability EPS (Most Recent Fiscal Year)($0.75) Net Income$-26,610,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-90.95%Miscellaneous Employees29 Outstanding Shares111,320,000Market Cap$93.62 million Next Earnings Date3/5/2020 (Estimated) OptionableOptionable Receive SNSS News and Ratings via Email Sign-up to receive the latest news and ratings for SNSS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SNSS Rates by TradingView Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions What is Sunesis Pharmaceuticals' stock symbol? Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS." How were Sunesis Pharmaceuticals' earnings last quarter? Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) posted its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.10) by $0.04. View Sunesis Pharmaceuticals' Earnings History. When is Sunesis Pharmaceuticals' next earnings date? Sunesis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Sunesis Pharmaceuticals. What price target have analysts set for SNSS? 3 brokers have issued 1 year price targets for Sunesis Pharmaceuticals' stock. Their forecasts range from $1.50 to $6.00. On average, they expect Sunesis Pharmaceuticals' stock price to reach $3.75 in the next year. This suggests a possible upside of 345.9% from the stock's current price. View Analyst Price Targets for Sunesis Pharmaceuticals. What is the consensus analysts' recommendation for Sunesis Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sunesis Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sunesis Pharmaceuticals. What are Wall Street analysts saying about Sunesis Pharmaceuticals stock? Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock: 1. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (1/15/2020) 2. HC Wainwright analysts commented, "Our $267 price target is derived from a risk-adjusted (does not include CMT or Sanfilippo A) DCF analysis and is based on: beta of 1.79, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.7%, and tax rate of 15% beginning in FY 2024." (6/17/2019) Has Sunesis Pharmaceuticals been receiving favorable news coverage? News headlines about SNSS stock have been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Sunesis Pharmaceuticals earned a daily sentiment score of 2.3 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Sunesis Pharmaceuticals. Are investors shorting Sunesis Pharmaceuticals? Sunesis Pharmaceuticals saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 1,290,000 shares, a decrease of 46.0% from the January 15th total of 2,390,000 shares. Based on an average daily trading volume, of 2,061,600 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.3% of the shares of the stock are short sold. View Sunesis Pharmaceuticals' Current Options Chain. Who are some of Sunesis Pharmaceuticals' key competitors? Some companies that are related to Sunesis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Sunesis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sunesis Pharmaceuticals investors own include SLS International (SLS), NVIDIA (NVDA), QUALCOMM (QCOM), Exelixis (EXEL), Micron Technology (MU), Novavax (NVAX), VBI Vaccines (VBIV), Actinium Pharmaceuticals (ATNM), Aduro BioTech (ADRO) and Progenics Pharmaceuticals (PGNX). Who are Sunesis Pharmaceuticals' key executives? Sunesis Pharmaceuticals' management team includes the folowing people: Mr. Dayton Misfeldt, Interim CEO & Director (Age 45)Mr. William P. Quinn, Sr. VP of Fin. & Corp. Devel. and CFO (Age 48)Mr. Daniel N. Swisher Jr., Strategic Advisor (Age 56)Mr. Gene C. Jamieson, VP of Technical OperationsDr. Judith A. Fox, Chief Scientific Officer Who are Sunesis Pharmaceuticals' major shareholders? Sunesis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Samsara BioCapital LLC (5.33%), Geode Capital Management LLC (0.57%), Ikarian Capital LLC (0.10%) and BCS Wealth Management (0.07%). Company insiders that own Sunesis Pharmaceuticals stock include Aisling Capital Iv, Lp and William P Quinn. View Institutional Ownership Trends for Sunesis Pharmaceuticals. Which major investors are buying Sunesis Pharmaceuticals stock? SNSS stock was bought by a variety of institutional investors in the last quarter, including Samsara BioCapital LLC, Ikarian Capital LLC, BCS Wealth Management and Geode Capital Management LLC. Company insiders that have bought Sunesis Pharmaceuticals stock in the last two years include Aisling Capital Iv, Lp and William P Quinn. View Insider Buying and Selling for Sunesis Pharmaceuticals. How do I buy shares of Sunesis Pharmaceuticals? Shares of SNSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Sunesis Pharmaceuticals' stock price today? One share of SNSS stock can currently be purchased for approximately $0.84. How big of a company is Sunesis Pharmaceuticals? Sunesis Pharmaceuticals has a market capitalization of $93.62 million and generates $240,000.00 in revenue each year. The biopharmaceutical company earns $-26,610,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. Sunesis Pharmaceuticals employs 29 workers across the globe.View Additional Information About Sunesis Pharmaceuticals. What is Sunesis Pharmaceuticals' official website? The official website for Sunesis Pharmaceuticals is http://www.sunesis.com/. How can I contact Sunesis Pharmaceuticals? Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected] MarketBeat Community Rating for Sunesis Pharmaceuticals (NASDAQ SNSS)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 388 (Vote Outperform)Underperform Votes: 427 (Vote Underperform)Total Votes: 815MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNSS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNSS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2020 by MarketBeat.com StaffFeatured Article: Do You Need a Fiduciary?
